Sarcopenia, the age-related loss of muscle mass and strength, has no approved drug treatment anywhere in the world. This study reports that imeglimin, a first-in-class oral antidiabetic already licensed in Japan under the name Twymeeg, preserved skeletal muscle in two independent mouse models of muscle loss. In obese mice, six weeks of treatment restored shrunken fast-twitch fibres in the extensor digitorum longus to the size seen in lean animals, a 66 percent increase over untreated obese co...